Big Pharma Shenanigans


For those of you who are interested in the shenanigans of the Pharma industry, Forward Pharma have put out a press release that they are raising money to develop their version of dimethyl fumarate for MS and psoriasis. We assume Biogen-Idec will contest this. Forward Pharma’s action are likely to result in a length and expensive legal battle, unless Forward Pharma simply want a big payout.

FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)

Forward Pharma is focused on advancing its lead drug candidate FP187. The compound is based on the small molecule dimethylfumarate (DMF) in a patented controlled release erosion matrix tablet with enteric coating. FP187 is being developed for possible treatment of immune disorders including multiple sclerosis and psoriasis. Forward Pharma expects to approach other immune disorders exploiting the immunmodulatory properties of the compound in immunology.

DMF is thought to interact with T cells and dendritic cells in the gut and pre-systemic circulation inducing an anti-inflammatory cellular and cytokine profile. It is also thought that DMF has direct cytoprotective effects. Importantly, DMF does not appear to induce significant immunosuppression at clinical doses1,2.

The development of FP187 benefits from the unique situation of a long term track record of DMF in Germany, where a DMF formulation combined with three salts of monoethylfumarate was approved for psoriasis in 1994 (Fumaderm)3, and has gained first-line status and endorsement in German and international guidelines since then4,5,6. FP187 development is based on evidence that DMF is the most essential component in this formulation. With FP187 Forward Pharma aims to provide a more tolerable, more convenient, long-term effective oral therapy for patients with immune disorders.

FP187 has demonstrated promising controlled release characteristics and tolerability in Phase I testing in healthy volunteers. More recently, FP187 has successfully completed a large randomized, double-blind, placebo-controlled registration study in patients with moderate to severe psoriasis (, EudraCT No.: 2010-020168-39).

Forward Pharma Files Registration Statement for Initial Public Offering

Copenhagen, Denmark – August 11, 2014 – Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined. Forward Pharma intends to list its ordinary shares on the NASDAQ under the ticker symbol “FWP.”

The offering will be made only by means of a prospectus. 

A registration statement relating to Forward Pharma’s securities has been filed with the United States Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About the author



Leave a Reply to Anonymous Cancel reply

  • Pharmaceutical companies market drugs to make a profit, as with any other company. They are using drugs to manage disease. The longer the patient is on a medication the better for their bottom line. Chronic diseases such as MS are a cash cow. This site is a good source for the latest news in MS but posts such as this do nothing to further the understanding of the disease.

    • My god, this blog has some of the whiniest people I have ever seen on the internet. If you don't like the post, just don't view it. This blog covers the entire spectrum of MS topics, and it's not here as your personal pep-rally or to cover exactly what you want. Prof G, Prof B, and everyone else on this blog are donating their time to bring information to those of us with MS. If you have constructive feedback on what you'd like to see more of, I'm sure everyone would love to hear it, but if you're just going to complain, keep your thoughts to yourself.

    • …… MS but posts such as this do nothing to further the understanding of the disease.

      Not true, it tells us that the patents on DMF are weak and if one company can break them them another and then another. This may mean cheap drugs for people who can't afford to buy them.

    • Sorry to say there is nothing in the pharma portfolio that means cheap drugs, the only way for a cheap drug is non-pharma to develop them,but this can't be done unless there is a change in the process, pharma are the only ones that can afford the current process.

    • If there is enough competition then drug prices are bound to fall EVENTUALLY. Even if it hasn't happened yet

      But suppose we reach 15-20 approved therapies. Then they cannot all charge the current rates. Somebody will reduce prices

    • however it appears to be a cartel. The biologicals all need trials to gain market access…extevia is supposed to be a generic of betaseron yet the price is not that lower, the coxapones me toos I suspect will be about 10% cheaper..however in US teva put price up as its patent was expiring. Gilenya has the first patent for a small molecule to expire then it could be game on

    • This drug is just tecfidera with an enteric coating, similar to analgesics, for patients who have gastric issues with aspirin. Its not a new drug with a novel mode of action. This is similar to Biogen attaching a PEG molecule on beta interferon. The bioavailability is increased (less frequent dosing) but the mechanism is unchanged. Just buy some gelatin capsules and dimethyl fumarate from Sigma (about $20 (U.S) for a years supply).

    • If this really any different to normal pharma practise,one finds a target and they all follow, isn't that why we had 3 beta intereferons. In these type of cases the lawyers get rich and then there is a mutually beneficial deal is done. The company with the biggest pockets may win as you get out lawyered.

      This is an advertisement for cash.

By BartsMSBlog



Recent Posts

Recent Comments